The primary objective of this analysis was to evaluate the impact of various revascularization strategies versus the current standard, which is target/ culprit lesion revascularization, in patients presenting with ST-Elevation Myocardial Infarction. Data extracted from each trial included: 1) study details, including year, location, country, numbers of centers involved, duration of followup, number of patients, proportion of male patients, number of procedures, angiographic data, type of catheter-based therapy; 2) mortality outcomes, including all-cause, cardiovascular and non-cardiovascular mortality at end of reported follow up; 3) hemodynamic outcomes including technical success, presence of hemodynamic instability both before and after catheter-based 2
interventions, presence and improvement of left ventricular dysfunction, and occurrence of cardiac arrest prior to catheter-based intervention and peri-procedural and post-procedural cardiac arrest, 4) safety outcomes including minor and major access site bleeding, hemoptysis, bleeding at other sites, and intracranial bleeding. Multiple investigators performed data extraction (NSB, PA, RK). All investigators involved in data extraction (NSB, PA, RK) also checked for consistency before full-scale data extraction was carried out. All discrepancies in data extraction were resolved by mutual consensus.
Statistical analysis
After the data elements were verified for accuracy, systematic and statistical analyses were conducted using Comprehensive Meta-Analysis version 2 (Biostat, Englewood, New Jersey) and STATA, version 14.0 (StataCorp LP), respectively. We used random effects modeling for all analyses. We assessed for heterogeneity using the I 2 test (I 2 >50% with p-value < 0.05 considered as evidence of significant heterogeneity). We also performed a pre-specified subgroup analysis to assess the role of Fractional flow reserve (FFR) in patients undergoing complete revascularization (CR). Publication bias for the primary outcome was assessed using the funnel plot and Eggers regression method and was considered significant if the one tailed pvalue was < 0.05. If significant publication bias was present, corrected estimates were calculated using the Duval and Tweedie trim and fill method. The analysis was reported in accordance with the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) guidelines. 
Hemodynamic instability
Defined as patients with a systolic blood pressure less than 90 mmHg, a systolic blood pressure drop greater than 40mmHg drop for 15 minutes or more, or exhibiting a requirement for inotropic or vasopressor support. Shock index >1 was also used to define hemodynamic instability where the authors stated individual patients' heart rate and blood pressure readings. Additionally, any patients described as being hemodynamically unstable by the authors (without a definition) and patients who had experienced cardiac arrest immediately prior to the procedure were also defined as being hemodynamically unstable.
Complete revascularization
Revascularization of the culprit artery and all flow-limiting epicardial coronary arteries.
Staged revascularization
Revascularization of the culprit artery with later elective revascularization of all flow-limiting epicardial coronary arteries.
Culprit lesion revascularization
Revascularization of culprit artery only.
Re-infarction
As defined by ACC/AHA/SCAI guidelines or as defined by authors 1,2 . In-stent thrombosis Defined as either angiographically confirmed partial or complete occlusion of stent or repeat myocardial infarction in the distribution of the revascularized vessel.
All-cause mortality
All deaths till the end of the follow-up period after being discharged from the index hospitalization. Where follow-up beyond discharge was not reported, this was the same as survival to discharge. The cause of death was further sub-divided into cardiovascular mortality and non-cardiovascular mortality. Where the cause of death could not be defined, the death was counted towards all-cause mortality without being included in the 'cardiovascular mortality' or 'non-cardiovascular mortality' sub-groups. Major adverse cardiac event (MACE) Due to the heterogeneity in definitions amongst the included trials we defined MACE as follows: mortality including all-cause death, any new myocardial infarction (fatal and non-fatal myocardial infarctions), and revascularization with either percutaneous coronary intervention or coronary artery bypass grafting. Cardiovascular mortality Death due to ventricular failure, myocardial infarction, or cardiac arrest till the end of the follow-up period.
Non-cardiovascular mortality
Death from all causes aside from those listed in 'cardiovascular mortality'.
Major bleeding
Major bleeding was defined as follows: major visceral bleeding as defined by authors (including intracranial hemorrhage); any bleeding requiring operative intervention or transfusion of at least two units of packed red blood cells; bleeding leading to shock as defined above.
Minor bleeding
Any other bleeding event that was not considered major bleeding.
Contrast-induced nephropathy (CIN)
Defined as the worsening of renal function after administration of radioactive contrast material. Per SCAI guidelines, CIN was defined as increase in serum baseline creatinine over 48 hours by >25% or an absolute increase of 0.25-0.5 mg/dl.
1,2
Stroke Any new focal neurologic deficit of suspected vascular origin persisting beyond 24 hours or as defined by authors. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.
9
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).
6-9
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.
9-12
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.
Risk of bias across studies 9 and 12 DISCUSSION Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).
13-16
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.
16-17
FUNDING Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. The blue solid lines represent the confidence intervals for log odds ratios for each comparison in individual studies and the green solid lines represents log odds ratio within study design and blue solid line represents respective overall log odds ratio using consistency and inconsistency models. The black dashed line is no effect (odds ratio equal to 1). CR = complete revascularization at index angiogram; SR = staged revascularization of non-culprit vessels after culprit lesion revascularization ay index angiogram; CL = culprit lesion revascularization only at index angiogram 
